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Abstract
The Journal of Translational Medicine is pleased to announce a prize to recognize outstanding
contributions in the field of translational medicine. This year, the Bedside-to-Bench Award was
provided by an anonymous donor and supported by the Journal of Translational Medicine Editorial
Board. Applications should be submitted directly to the Journal of Translational Medicine [1].
Honoring the legacy of patients by promoting 
clinically-relevant, evidence-based research
"And then did we, the seven, start from our seats in horror, and
stand trembling and shuddering, and aghast, for the tones in
the voice of the shadow were not the tone of any one being, but
of a multitude of beings, and, varying in their cadences from
syllable to syllable, fell duskily upon our ears in the well-remem-
bered and familiar accents of many thousand departed friends"
Edgar Allan Poe – "Shadow – A parable"
When a patient dies, clinical scientists have a legacy to pre-
serve. I am reminded of parents who visited my laboratory
following the death of their son; they asked the cell lines
growing from his fatal cancer be named after him. Patients
die in serene dignity hoping for their sole consolation that
their torment was not in vain; Jonathan Gray died in the
Fall of 2007 after preparing a moving editorial about his
experience as a cancer patient and leaving suggestions for
survivors. Recently, we published an Editorial emphasiz-
ing the need to encourage discovery-driven research as a
complement to hypothesis testing to better frame experi-
mentation in the context of disease relevance [2]. The Edi-
torial expanded on the theme of the one that
accompanied the launch of the Journal of Translational
Medicine in which we suggested that translational research
is a two way street where the bedside-to-bench direction
plays a Cinderella's role [3]. The intellectual flaws of a
purely hypothesis-driven approach to translational
research are discussed, but less discussed are the impor-
tant ethical aspects of applying discovery-driven research
to clinical medicine. I believe we owe to our patients, par-
ticularly those who submit themselves to demanding clin-
ical trials with no guaranteed benefit that their suffering
shall not be wasted and their medical history shall not be
forgotten. For our patients their tissues are a precious leg-
acy to be remembered and represent their hope of saving
other.
It has been almost five years since July 2003 when we
launched the Journal of Translational Medicine as an open
access journal dedicated to appropriate peer review and
rapid publication of results generated by clinical investi-
gations. The journal has since received enthusiastic inter-
national support and has been rapidly recognized and
tracked/indexed by PubMed [4], PubMed Central [5],
Medline [6], Thompson Scientific (ISI) [7], CAS [8],
Embase [9] and Scopus [10]. The journal will receive it
first official impact factor in June of 2008. This year we
granted the first Excellence in Translational Medicine
Published: 22 April 2008
Journal of Translational Medicine 2008, 6:20 doi:10.1186/1479-5876-6-20
Received: 17 January 2008
Accepted: 22 April 2008
This article is available from: http://www.translational-medicine.com/content/6/1/20
© 2008 Marincola; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Translational Medicine 2008, 6:20 http://www.translational-medicine.com/content/6/1/20
Page 2 of 2
(page number not for citation purposes)
Award sponsored by Pfizer [11]. The award has broader
goals and was granted this year by a stringent review proc-
ess lead by Richard Ablin to an excellent bench-to-bedside
study [12]. A second award will be dedicated to Bedside-
to-Bench studies defined as those exclusively based on the
study of human samples [13,14].
The bedside-to-bench award in translational 
research
The recipient of The Excellence in Translational Medicine
Award will receive a $5,000 prize to cover expenses for any
meeting sponsored by a non-for-profit organization that
is relevant to the goal of translational medicine/research.
Submitted articles will be evaluated with regard to: rele-
vance to translational medicine/research based on discov-
ery-driven, evidence-based studies aimed at
understanding human pathology by the direct study of
human subjects. Selection criteria will include use of
human samples not including cell lines or other tissue
products expanded in vitro for more than one week, scien-
tific merit, sound research design, rigorous methodology,
originality and clarity.
Eligibility criteria and selection process
• The award will be granted to the first author of a research
manuscript containing original data published in the Jour-
nal of Translational Medicine between January 1 and
December 31 of each year.
￿ Candidates may be self-nominated or nominated by a
colleague
￿ Candidates must be the primary clinician or investigator
involved in the project described by the article. If there are
multiple first authors, each first author of the selected
manuscript may claim designation as a candidate. In the
event of multiple authors sharing the Award, the prize will
be divided equally among them. If there are multiple first
authors, this must be indicated at the time of submission.
￿ Authors from laboratories of the members of the selec-
tion committee are not eligible for the Award.
Evaluation criteria
Submitted articles will be evaluated with regard to:
￿ Relevance to the purposes of translational medicine/
research presenting discovery-driven, evidence-based
studies aimed at the understanding of human pathology
by the direct study of human subjects
￿ Scientific merit





All applications should be submitted to the Journal of
Translational medicine – Awards Section [1].
Selection Committee
Selection will be made by a committee of members of the
Editorial Board.
We hope the Bedside-to-Bench Award together with the
Excellence in Translational Medicine Award will encour-
age and reward those investigators who are dedicated to
improving the efficiency of biomedical research with the
goal of preventing and/or effectively treat human disease.
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